Evidence map›Paper›PMID 38900343›Full record

SynthesisJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2024

Preclinical Studies on Mechanisms Underlying the Protective Effects of Propranolol in Traumatic Brain Injury: A Systematic Review.

James Jae, Yilong Li, Clara Sun, Alison Allan, John Basmaji, Stephanie Chilton, Mohammad Hmidan Simsam, Raymond Kao, Adrian Owen, Neil Parry and 8 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

James JaeDepartment of Medicine, Western University, London, ON, Canada.
Yilong LiDepartment of Microbiology and Immunology, Western University, London, ON, Canada.
Clara SunMichael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Alison AllanDepartment of Anatomy and Cell Biology, Western University, London, ON, Canada.
John BasmajiDepartment of Medicine, Western University, London, ON, Canada.
Stephanie ChiltonDepartment of Medicine, Western University, London, ON, Canada.
Mohammad Hmidan SimsamSchulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Raymond KaoDepartment of Medicine, Western University, London, ON, Canada.
Adrian OwenBrain and Mind Institute, Western University, London, ON, Canada.
Neil ParryLondon Health Sciences Trauma Program, London, ON, Canada.
Fran PriestapLondon Health Sciences Trauma Program, London, ON, Canada.
Bram RochwergDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Shane SmithLondon Health Sciences Trauma Program, London, ON, Canada.
Alexis F TurgeonCHU de Québec - Université Laval Research Center, Population Health and Optimal Health Practices Research Unit (Trauma-Emergency-Critical Care Medicine), Québec City, Québec, Canada.
Kelly VogtLondon Health Sciences Trauma Program, London, ON, Canada.
Eric WalserDepartment of Medicine, Western University, London, ON, Canada.
Alla IansavitcheneHealth Sciences Library, London Health Sciences Center, London, ON, Canada.
Ian BallDepartment of Medicine, Western University, London, ON, Canada. Ian.Ball@lhsc.on.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traumatic brain injury (TBI) is a leading cause of mortality and morbidity amongst trauma patients. Its treatment is focused on minimizing progression to secondary injury. Administration of propranolol for TBI maydecrease mortality and improve functional outcomes. However, it is our sense that its use has not been universally adopted due to low certainty evidence. The literature was reviewed to explore the mechanism of propranolol as a therapeutic intervention in TBI to guide future clinical investigations. Medline, Embase, and Scopus were searched for studies that investigated the effect of propranolol on TBI in animal models from inception until June 6, 2023. All routes of administration for propranolol were included and the following outcomes were evaluated: cognitive functions, physiological and immunological responses. Screening and data extraction were done independently and in duplicate. The risk of bias for each individual study was assessed using the SYCLE's risk of bias tool for animal studies. Three hundred twenty-three citations were identified and 14 studies met our eligibility criteria. The data suggests that propranolol may improve post-TBI cognitive and motor function by increasing cerebral perfusion, reducing neural injury, cell death, leukocyte mobilization and p-tau accumulation in animal models. Propranolol may also attenuate TBI-induced immunodeficiency and provide cardioprotective effects by mitigating damage to the myocardium caused by oxidative stress. This systematic review demonstrates that propranolol may be therapeutic in TBI by improving cognitive and motor function while regulating T lymphocyte response and levels of myocardial reactive oxygen species. Oral or intravenous injection of propranolol following TBI is associated with improved cerebral perfusion, reduced neuroinflammation, reduced immunodeficiency, and cardio-neuroprotection in preclinical studies.

Indexed as

Brain Injuries, TraumaticPropranololAdrenergic beta-AntagonistsAnimalsDisease Models, AnimalDrug Evaluation, PreclinicalHumansNeuroprotective AgentsAdrenergic beta-AntagonistsNeuroprotective AgentsPropranololBeta-blockadeCognitionPropranololTraumatic brain injury

Identifiers

PMID38900343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.